10 Aug, 2020 RNAi Roundtable: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type 1
Posted at 14:00h
in Capella
On August 10, 2020, we hosted an online RNAi Roundtable to review progress with lumasiran, an RNAi therapeutic in development for the treatment of primary hyperoxaluria type 1.
Access the replay
View the presentation
Read the transcript
Pritesh Gandhi, PharmD.
Vice President & General Manager, Lumasiran
Michael J.G. Somers, M.D.
Associate Chief and Gunnar B. Stickler Chair in Pediatric Nephrology, Division of Nephrology and Medical Director, Renal Dialysis Unit, Boston Children’s Hospital; Associate Professor of Pediatrics, Harvard Medical School; President, American Society of Pediatric Nephrology
Tracy McGregor, M.D.
Senior Director, Clinical Research
